©The Author(s) 2026. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastrointest Oncol. Feb 15, 2026; 18(2): 114163
Published online Feb 15, 2026. doi: 10.4251/wjgo.v18.i2.114163
Published online Feb 15, 2026. doi: 10.4251/wjgo.v18.i2.114163
Role of microRNA-136 in Helicobacter pylori-induced early-stage gastric cancer: Mechanistic insights and future directions
Yi-Xiao Chen, Ying-Hua Zhang, Sai-Jun Mo, Department of Pathophysiology, School of Basic Medical Sciences, Zhengzhou University, Zhengzhou 450001, Henan Province, China
Co-first authors: Yi-Xiao Chen and Ying-Hua Zhang.
Author contributions: Chen YX and Zhang YH contributed equally to this manuscript and are co-first authors. Chen YX, Zhang YH, and Mo SJ participated in the revision of the manuscript; Mo SJ conceived the idea of the manuscript, and approved the final version; Chen YX drafted the main content of the manuscript. All authors have read and approved the final manuscript.
Supported by Foundation of Henan Educational Committee, No. 26A310017; Natural Science Foundation for Young Teachers’ Basic Research of Zhengzhou University, No. JC202035025; and College Student Innovation and Entrepreneurship Competitions, No. 202510459174 and No. 2025cxcy639.
Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.
Corresponding author: Sai-Jun Mo, PhD, Associate Professor, Department of Pathophysiology, School of Basic Medical Sciences, Zhengzhou University, No. 100 Science Avenue, Zhong
Received: September 15, 2025
Revised: October 8, 2025
Accepted: December 3, 2025
Published online: February 15, 2026
Processing time: 143 Days and 18.3 Hours
Revised: October 8, 2025
Accepted: December 3, 2025
Published online: February 15, 2026
Processing time: 143 Days and 18.3 Hours
Core Tip
Core Tip: This study identified microRNA-136 as a potential diagnostic biomarker and therapeutic target for early-stage gastric cancer, demonstrating its role in tumor growth and metastasis through in vitro and in vivo models. Targeting the nuclear factor kappa B/microRNA-136/programmed cell death protein 11 axis may offer new strategies for intervention.